New insider activity at Serina Therapeutics ( (SER) ) has taken place on May 22, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Director Richard Peter Marshall has increased his stake in Serina Therapeutics by purchasing 12,183 shares of the company’s stock in a recent transaction valued at $20,101, signaling a fresh vote of confidence from inside the company’s leadership.
Recent Updates on SER stock
Serina Therapeutics’ shares faced pressure after the company filed to register 16.45M existing shares for resale, raising concerns about potential selling overhang and dilution for current holders. Investors are also reacting to the previously disclosed insider-backed PIPE, which concentrates ownership and governance power with participating investors, elevating perceived conflict-of-interest and governance risks that could increase volatility and weigh on sentiment despite the long-term upside narrative reflected in current analyst targets.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
Overall score is held back primarily by weak financial performance (minimal revenue, large losses, and significant cash burn) and bearish technical trends (below major moving averages with negative MACD). Offsetting these, corporate events are a near-term positive due to added funding runway and governance/leadership actions, but valuation support is limited given ongoing losses and no dividend.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
YTD Price Performance: -1.20%
Average Trading Volume: 3,202,646
Technical Sentiment Signal: Sell
Current Market Cap: $25.5M